The Amazon-Berkshire-JPM team makes a new appointment

By Catherine Sturman
Technology companies are increasingly entering the health space with enthusiasm and determination. The recent partnership of Amazon, Berkshire Hathaway...

Technology companies are increasingly entering the health space with enthusiasm and determination. The recent partnership of Amazon, Berkshire Hathaway and JPM is no exception.

Hiring a number of renowned healthcare experts in their chosen fields, Dana Gelb Safran, Senior Vice President of enterprise analytics at Blue Cross Blue Shield, has become the recent appointment which will further set the trio’s healthcare ambition alight.

Following on from the appointment of Atul Gawande in June, who has voiced his plans to incubate better models of care for all, the hiring of Safran will enable the trio to increasingly look at ways to lower healthcare costs and drive positive patient outcomes through the use of advanced data analytics.

See also

In her role as Chief Performance Measurement and Improvement Officer and Senior Vice President of Enterprise Analytics, Safran will become the first woman hired by the trio when she joins the venture early next year as Head of Measurement.

This year, Amazon has been making significant advances in healthcare. From its acquisition of online pharmacy start-up, PillPack to its partnership with blockchain innovator Ethereum, the tech giant has now begun to sell glucose monitors and blood pressure technologies direct to consumers, further accelerating its desire to disrupt the market

Share

Featured Articles

Comarch Diagnostic Point Boost for European Health Insurance

Healthtech specialist Comarch introduces Diagnostic Point, designed to improve health insurance across European markets

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Procurement & Supply Chain

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma